EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, has announced the appointment of Scott Filosi as Senior Vice President of Managed Markets. Filosi brings extensive specialty pharmaceutical experience with a focus on managed markets, global business development and market access for biologics. He has led national and regional accounts teams including federal, field reimbursement, contracting and health outcomes.
As Senior Vice President of Managed Markets, Filosi will be responsible for developing and executing Managed Markets marketing, sales, and contracting strategies to ensure optimal market access and pull through for EMD Serono products for patients, as well as reimbursement strategies for the oncology portfolio. He is also responsible for leading specialty pharmacy patient adherence and retention programs.
"Mr. Filosi brings to us a successful track record of driving operational growth and performance for mid-sized specialty pharmaceutical market access teams," said Gary Zieziula, Chief Commercial Officer of EMD Serono. "He's well-positioned to lead a strong managed markets team, continuing to drive successful strategies for our specialty care portfolio which will help us deliver our medicines effectively to patients."
Prior to joining EMD Serono, Filosi was the Head of U.S. Market Access and Pricing and the Head of Established Brands in the U.S., and led business operations for Canada and Mexico at UCB Pharma. In this role, he had full Profit and Loss (P&L) responsibility for the established brands and led contracting, access, distribution, reimbursement, access strategy, health outcomes and channel forecasting.
Previous to UCB, Filosi was Vice President of Global Business Development at i3 Innovus where he led the U.S. and EU business development model design and implementation for health outcomes. Prior to joining i3 Innovus, Filosi spent six years with Boehringer Ingelheim and 13 years with Johnson & Johnson in a variety of commercial and sales roles.